Gene Editing Could Limit Toxicity of CAR T Treatment in AML

Article

A study recently published in Cell investigated the deletion of the CD33 protein to enable CAR T-cells to more accurately target and attack cancerous cells in patients with n acute myeloid leukemia (AML).

A study recently published in Cell may have identified a new approach to limit the toxicity of chimeric antigen receptor (CAR) T-cell treatment in acute myeloid leukemia (AML).

To treat AML with CAR T-cells, researchers genetically alter an individual’s immune cells to target CD33, a specific protein that is expressed on both cancerous and healthy hematopoietic stem and progenitor cells (HSPCs). Previously, this meant that the treatment would attack cancer cells as well as healthy HSPCs and eventually lead to toxicity in patients.

To make treatment more effective, researchers used a gene editing tool, CRISPR/Cas9, to remove CD33 from HSPCs. Study authors have described the approach as a “next-generation hematopoietic stem cell transplant.”

The study found that cells that had the CD33 protein removed functioned normally with no identifiable difference. This may be because “while CD33 does have a suppressive function, other inhibitory cell surface receptors can compensate for loss of CD33.” Previous studies have also found no evidence of abnormalities in CD33-deficient mice, suggesting that the loss of the protein may be well tolerated.

Researchers studied this approach in both mouse and monkey models, as well as human cells in a laboratory setting, and found it to be effective. The next step is for researchers to study the approach in human trials. Despite promising results in the laboratory, researchers have noted that they intend to proceed with caution. “We cannot definitively exclude the possibility of occult functional defects in CD33 [knockout] myeloid cells that may manifest when this therapy is extended to human subjects and followed long-term. Therefore, translation of this approach to humans will have to be undertaken carefully.”

If successful, this approach could potentially be extended to other cell-surface antigens or forms of antigen-specific immunotherapy, such as monoclonal antibodies. Given the success researchers have seen thus far, the approach is anticipated to have a wide therapeutic range offering a variety of treatment modalities in AML.

Reference

Kim M, Yu K, Kenderian S, et al. Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia. Cell. 2018;173(6):14339-1453. doi: 10.1016/j.cell.2018.05.013.

Recent Videos
David Barrett, JD, the chief executive officer of ASGCT
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
David Barrett, JD, the chief executive officer of ASGCT
Alfred L. Garfall, MD, MS, associate professor of medicine (hematology-oncology) and director, Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program, Hospital of the University of Pennsylvania; and section chief, Multiple Myeloma, Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Nirav Shah, MD, MSHP, associate professor of medicine, at the Medical College of Wisconsin
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Mark Hamilton, MD, PhD, a hematology-oncology and bone marrow transplant (BMT) cell therapy fellow at Stanford University
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Related Content
© 2025 MJH Life Sciences

All rights reserved.